Enhanced lymphocyte interferon (IFN)‐γ responses in a PTEN mutation‐negative Cowden disease kindred

R. Stevenson,A. Fatehullah,I. Jagan,R. Deevi,Victoria Bingham,A. Irvine,Marilyn A. Armstrong,P. J. Morrison,I. Dimmick,R. Stewart,Frederick Charles Campbell
DOI: https://doi.org/10.1111/j.1365-2249.2011.04336.x
2011-05-01
Abstract:Identification of immune modifiers of inherited cancer syndromes may provide a rationale for preventive therapy. Cowden disease (CD) is a genetically heterogeneous inherited cancer syndrome that arises predominantly from germline phosphatase and tensin homologue deleted on chromosome 10 (PTEN) mutation and increased phosphoinositide 3‐kinase/mammalian target of rapamycin (PI3K/mTOR) signalling. However, many patients with classic CD diagnostic features are mutation‐negative for PTEN (PTEN M‐Neg). Interferon (IFN)‐γ can modulate the PI3K/mTOR pathway, but its association with PTEN M‐Neg CD remains unclear. This study assessed IFN‐γ secretion by multi‐colour flow cytometry in a CD kindred that was mutation‐negative for PTEN and other known susceptibility genes. Because IFN‐γ responses may be regulated by killer cell immunoglobulin‐like receptors (KIR) and respective human leucocyte antigen (HLA) ligands, KIR/HLA genotypes were also assessed. Activating treatments induced greater IFN‐γ secretion in PTEN M‐Neg CD peripheral blood lymphocytes versus healthy controls. Increased frequency of activating KIR genes, potentially activating KIR/HLA compound genotypes and reduced frequency of inhibitory genotypes, were found in the PTEN M‐Neg CD kindred. Differences of IFN‐γ secretion were observed among PTEN M‐Neg CD patients with distinct KIR/HLA compound genotypes. Taken together, these findings show enhanced lymphocyte secretion of IFN‐γ that may influence the PI3K/mTOR CD causal molecular pathway in a PTEN mutation‐negative CD kindred.
What problem does this paper attempt to address?